User profiles for "author:Andrea Sbrana"
Andrea SbranaDepartment of Translational Research and New Technologies in Medicine and Surgery Verified email at studenti.unipi.it Cited by 646 |
[HTML][HTML] Interprofessional spiritual care in oncology: a literature review
CM Puchalski, A Sbrana, B Ferrell, N Jafari, S King… - ESMO open, 2019 - Elsevier
Spiritual care is recognised as an essential element of the care of patients with serious
illness such as cancer. Spiritual distress can result in poorer health outcomes including …
illness such as cancer. Spiritual distress can result in poorer health outcomes including …
Multinational Association of Supportive Care in Cancer (MASCC) expert opinion/consensus guidance on the use of cannabinoids for gastrointestinal symptoms in …
B Alderman, D Hui, S Mukhopadhyay… - Supportive Care in …, 2023 - Springer
Background Gastrointestinal symptoms are common in patients with cancer, whether related
to treatment or a direct effect of the disease itself. Patients may choose to access …
to treatment or a direct effect of the disease itself. Patients may choose to access …
[PDF][PDF] Use of procalcitonin in clinical oncology: a literature review
A Sbrana, M Torchio, G Comolli, A Antonuzzo… - New …, 2016 - newmicrobiologica.org
The use of procalcitonin (PCT) as an early marker of infectious episodes in cancer patients
is still controversial. We performed a MEDLINE search of peer-reviewed articles published …
is still controversial. We performed a MEDLINE search of peer-reviewed articles published …
Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 …
Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC)
patients achieve a long-term benefit from immunotherapy. Moreover, the identification of …
patients achieve a long-term benefit from immunotherapy. Moreover, the identification of …
Multinational Association of Supportive Care in Cancer (MASCC) guidelines: cannabis for psychological symptoms including insomnia, anxiety, and depression
Purpose During the treatment of cancer, 18% of patients use cannabis for symptom
management. Anxiety, depression, and sleep disturbances are common symptoms in …
management. Anxiety, depression, and sleep disturbances are common symptoms in …
MASCC guideline: cannabis for cancer-related pain and risk of harms and adverse events
Background Approximately 18% of patients with cancer use cannabis at one time as
palliation or treatment for their cancer. We performed a systematic review of randomized …
palliation or treatment for their cancer. We performed a systematic review of randomized …
[HTML][HTML] Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists
M Ottaviano, M Curvietto, P Rescigno… - … for Immunotherapy of …, 2020 - ncbi.nlm.nih.gov
Background The coronavirus disease 2019 (COVID-19) pandemic has overwhelmed the
health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) …
health systems worldwide. Data regarding the impact of COVID-19 on cancer patients (CPs) …
[HTML][HTML] Impact of previous nephrectomy on clinical outcome of metastatic renal carcinoma treated with immune-oncology: a real-world study on behalf of Meet-URO …
M Stellato, D Santini, E Verzoni, U De Giorgi… - Frontiers in …, 2021 - frontiersin.org
Background Immune-Oncology (IO) improves Overall Survival (OS) in metastatic Renal Cell
Carcinoma (mRCC). The prognostic impact of previous Cytoreductive Nephrectomy (CN) …
Carcinoma (mRCC). The prognostic impact of previous Cytoreductive Nephrectomy (CN) …
Pancreatic resections for metastases: A twenty-year experience from a tertiary care center
G Di Franco, D Gianardi, M Palmeri, N Furbetta… - European Journal of …, 2020 - Elsevier
Background Literature data about pancreatic resections for metastases are limited to small
series, so that the role of surgery in this setting remains unclear. We herein report our …
series, so that the role of surgery in this setting remains unclear. We herein report our …
STYLE (NCT03449173): a phase 2 trial of sunitinib in patients with type B3 thymoma or thymic carcinoma in second and further lines
C Proto, S Manglaviti, GL Russo, M Musca… - Journal of Thoracic …, 2023 - Elsevier
Introduction Thymic malignancies are rare tumors with few therapeutic options. The STYLE
trial was aimed to evaluate activity and safety of sunitinib in advanced or recurrent type B3 …
trial was aimed to evaluate activity and safety of sunitinib in advanced or recurrent type B3 …